CH661045A5 - Wasserfreie, stabile kristalline form von prazosinhydrochlorid und verfahren zu dessen herstellung. - Google Patents

Wasserfreie, stabile kristalline form von prazosinhydrochlorid und verfahren zu dessen herstellung. Download PDF

Info

Publication number
CH661045A5
CH661045A5 CH5142/84A CH514284A CH661045A5 CH 661045 A5 CH661045 A5 CH 661045A5 CH 5142/84 A CH5142/84 A CH 5142/84A CH 514284 A CH514284 A CH 514284A CH 661045 A5 CH661045 A5 CH 661045A5
Authority
CH
Switzerland
Prior art keywords
prazosin hydrochloride
water
boiling point
anhydrate
stable
Prior art date
Application number
CH5142/84A
Other languages
German (de)
English (en)
Inventor
Stig Olof Engelbert Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of CH661045A5 publication Critical patent/CH661045A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
CH5142/84A 1984-06-25 1984-10-26 Wasserfreie, stabile kristalline form von prazosinhydrochlorid und verfahren zu dessen herstellung. CH661045A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
CH661045A5 true CH661045A5 (de) 1987-06-30

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
CH5142/84A CH661045A5 (de) 1984-06-25 1984-10-26 Wasserfreie, stabile kristalline form von prazosinhydrochlorid und verfahren zu dessen herstellung.

Country Status (17)

Country Link
US (2) US4739055A (enExample)
JP (1) JPS6115881A (enExample)
AT (1) AT389117B (enExample)
AU (1) AU566814B2 (enExample)
BE (1) BE900925A (enExample)
CH (1) CH661045A5 (enExample)
DE (1) DE3429415A1 (enExample)
FI (1) FI79107C (enExample)
FR (1) FR2567124B1 (enExample)
GB (1) GB2160861B (enExample)
IL (1) IL73267A (enExample)
IT (1) IT1224142B (enExample)
LU (1) LU85616A1 (enExample)
NL (1) NL8403250A (enExample)
NZ (1) NZ209962A (enExample)
PT (1) PT79411B (enExample)
ZA (1) ZA85910B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683760D1 (de) * 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体2―〔4―(2―フロイル)ピペラジン―1―イル〕―4―アミノ―6,7―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) * 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101657960B1 (ko) * 2008-08-15 2016-09-20 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE156532C (enExample) *
US2969375A (en) * 1961-01-24 Certification of correction
BE427505A (enExample) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Also Published As

Publication number Publication date
BE900925A (fr) 1985-02-15
NL8403250A (nl) 1986-01-16
FI79107C (fi) 1989-11-10
IT8423292A0 (it) 1984-10-24
LU85616A1 (fr) 1985-06-04
DE3429415A1 (de) 1986-01-02
JPH0481993B2 (enExample) 1992-12-25
IT1224142B (it) 1990-09-26
FI842544L (fi) 1985-12-26
ZA85910B (en) 1985-09-25
PT79411B (en) 1986-09-15
NZ209962A (en) 1987-06-30
AU3451084A (en) 1986-01-02
FR2567124B1 (fr) 1990-09-21
FI842544A0 (fi) 1984-06-25
US4873330A (en) 1989-10-10
GB8424999D0 (en) 1984-11-07
AT389117B (de) 1989-10-25
IL73267A0 (en) 1985-01-31
IL73267A (en) 1988-06-30
PT79411A (en) 1984-11-01
AU566814B2 (en) 1987-10-29
GB2160861B (en) 1987-11-18
GB2160861A (en) 1986-01-02
FR2567124A1 (fr) 1986-01-10
JPS6115881A (ja) 1986-01-23
DE3429415C2 (enExample) 1990-05-03
US4739055A (en) 1988-04-19
ATA344184A (de) 1989-03-15
FI79107B (fi) 1989-07-31

Similar Documents

Publication Publication Date Title
DE3429415A1 (de) Wasserfreie, stabile und kristalline form von prazosinhydrochlorid und verfahren zu dessen herstellung
DE2326784B2 (de) Verfahren zur Herstellung von Chinoxalin, insbesondere aus nicht gereinigten Rohstoffen
DE69917282T2 (de) Verfahren zur herstellung von zofenopril-calciumsalz
DE2502504C3 (de) Phenothiazinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
CH659464A5 (de) Verfahren zur herstellung von 1,8-dihydroxy-10-acyl-9-anthronen.
DE2253150C3 (de) Diastereoisomeres des 1- [1`-(o-Chlorbenzyl)-2-pyrryl]-2-di-(D,D)-sek.-butylaminoäthanols dessen Salze und Verfahren zur Herstellung dieser Verbindungen
DE2726258A1 (de) Verfahren zur herstellung von 5-fluoruracil
DE2166270C3 (de) Nicotinoylaminoäthansulfonyl-2amino-thiazol
DE1958514B2 (de) Apovincaminsaeureamid
DE3521456C2 (enExample)
DE1292664B (de) 1, 2, 3, 5, 6-Pentathiacycloheptan, Verfahren zu dessen Herstellung und Verwendung
DE1918253A1 (de) Verbessertes Verfahren zur Herstellung von 3-Hydroxyisoxazolverbindungen
DE2235998C3 (de) Phenothiazinderivate, ihre Herstellung und die pharmazeutischen Zusammensetzungen, die sie enthalten
DE1793462B2 (de) N-Aryl-anthranilsäureester monosubstituierter gem-Diole, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE1770351C2 (de) 2-0-Acyl-clindamycine, Verfahren zu deren Herstellung und diese Verbindungen enthaltende antibiotische Zubereitungen
DE949232C (de) Verfahren zur Herstellung therapeutisch wertvoller basischer substituierter Essigsaeureester
DE1445146C3 (de) Salze von 2-(Benzolsulfonamido)-5methoxyäthoxypyrimidinderivaten und deren Herstellung
DE1097995B (de) Verfahren zur Herstellung von Phenthiazinderivaten
DE2461132A1 (de) 7-halogenmethyl-17-hydroxy-3-oxo17alpha-pregn-4-en-21-carbonsaeure-gamma- lactone und verfahren zu ihrer herstellung
DE1182237B (de) Verfahren zur Herstellung von 10-[4'-Hydroxy-4'-hydroxyalkylpiperidinoalkyl]-phenthiazin-derivaten
AT269886B (de) Verfahren zur Herstellung neuer Benzomorphanderivate und ihrer Salze
DE2653398A1 (de) Verfahren zur herstellung von 5-fluor-uracil-derivaten
DE1645969C3 (de) Kristalline, teilweise dehydratisierte oder wasserfreie Formen von 6-(1 - Amirtocycloalkylcarboxamido) -penicillansäuren und Verfahren zu ihrer Herstellung
DE2657237A1 (de) Verfahren zur herstellung von isocyanursaeuretriestern
DE4108119A1 (de) Verfahren zur herstellung von 4'-chlor-2-((3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl) methylaminno) acetophenon und seiner salze, die stabilisierungseiner salze, hierbei erhaeltliche produkte und pharmmazeutische zubereitungen, die diese enthalten

Legal Events

Date Code Title Description
PL Patent ceased